Primary Sclerosing Cholangitis Treatment Market
Primary Sclerosing Cholangitis Treatment Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Primary Sclerosing Cholangitis Treatment Market Size and Growth
The Primary Sclerosing Cholangitis Treatment market is experiencing growth due to increasing diagnoses and evolving therapeutics. The market size is projected to reach USD 1 billion by 2028, driven by advancements in drug development and a rising patient population. Current treatments focus on symptom management and addressing disease progression.
Companies Covered
(Covid 19 Impact Covered)
◍ Allergan
◍ Glenmark
◍ Impax Laboratories
◍ Mylan
◍ Teva Pharmaceuticals
◍ Dr. Falk Pharma
◍ Daewoong Pharmaceutical
◍ Epic Pharma
◍ Mitsubishi Tanabe Pharma
◍ Lannett
◍ Bruschettini
◍ Shanghai Pharma
◍ Grindeks
◍ Acorda Therapeutics
◍ Gilead Sciences
◍ Intercept Pharmaceuticals
◍ Shire Plc
◍ NGM Biopharmaceuticals
The Primary Sclerosing Cholangitis (PSC) treatment market features companies like Gilead Sciences and Intercept Pharmaceuticals focusing on innovative therapies. Players such as Allergan and Teva Pharmaceuticals contribute with established drugs. Their combined efforts in R&D and market expansion enhance treatment options, driving growth in this niche segment.
Notable sales revenues include:
- Gilead Sciences: $27 billion (2022)
- Teva Pharmaceuticals: $15 billion (2022)
- Intercept Pharmaceuticals: $184 million (2022)
Request Sample Report
Market Segmentation
By Application
Hospital
Clinics
Other
Request Sample Report
By Product
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
Market Growth
Request Sample Report
$ 31.88 Million
